Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. Issue 3 (30th May 2014)

• Record Type: Journal Article
• Authors: Wells, Julia E.; Howlett, Meegan; Cole, Catherine H.; Kees, Ursula R.
• Is Part Of: International journal of cancer. Volume 137:Issue 3(2015:Aug. 01)
• Page Start: 504
• Page End: 511
• Publication Date: 2014-05-30
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28972
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Connective tissue growth factor <italic>(CTGF/CCN2)</italic> has long been associated with human cancers. The role it plays in these neoplasms is diverse and tumour specific. Recurring patterns in clinical outcome, histological desmoplasia and mechanisms of action have been found. When CTGF is overexpressed compared to low‐expressing normal tissue or is underexpressed compared to high‐expressing normal tissue, the functional outcome favours tumour survival and disease progression. CTGF acts by altering proliferation, drug resistance, angiogenesis, adhesion and migration contributing to metastasis. The pattern of <italic>CTGF</italic> expression and tumour response helps to clarify the role of this matricellular protein across a multitude of human cancers.</p> </abstract>